{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:01:58Z","timestamp":1774886518850,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019000","name":"Medical Affairs Bureau","doi-asserted-by":"publisher","award":["MND-MAB-115002"],"award-info":[{"award-number":["MND-MAB-115002"]}],"id":[{"id":"10.13039\/501100019000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02130-2","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:05:45Z","timestamp":1771859145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Agomelatine and the potential inverse risk of metabolic disorders: a nationwide cohort study with an active comparator design in Taiwan"],"prefix":"10.1186","volume":"18","author":[{"given":"Yuan-Liang","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chieh","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Cheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senyeong","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Ting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Yin","family":"To","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Bin","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"2","key":"2130_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0197-0186(94)90100-7","volume":"24","author":"PJ Morgan","year":"1994","unstructured":"Morgan PJ, Barrett P, Howell HE, Helliwell R. Melatonin receptors: Localization, molecular pharmacology and physiological significance. Neurochem Int. 1994;24(2):101\u201346.","journal-title":"Neurochem Int"},{"issue":"10","key":"2130_CR2","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.bcp.2008.02.022","volume":"75","author":"V Audinot","year":"2008","unstructured":"Audinot V, Bonnaud A, Grandcolas L, Rodriguez M, Nagel N, Galizzi J-P, et al. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Biochem Pharmacol. 2008;75(10):2007\u201319.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"2130_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00210-003-0751-2","volume":"367","author":"V Audinot","year":"2003","unstructured":"Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amoss\u00e9 C, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003;367(6):553\u201361.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2130_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/NDT.S5453","volume":"5","author":"RH Howland","year":"2009","unstructured":"Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat. 2009;5:563\u201376.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"15","key":"2130_CR5","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1111\/bph.12720","volume":"171","author":"B Guardiola-Lemaitre","year":"2014","unstructured":"Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Moca\u00ebr E. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171(15):3604\u201319.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"2130_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1586\/14737175.2014.908709","volume":"14","author":"R Mago","year":"2014","unstructured":"Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother. 2014;14(5):539\u201351.","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"2130_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40263-020-00763-z","volume":"34","author":"LM Behlke","year":"2020","unstructured":"Behlke LM, Lenze EJ, Carney RM. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs. 2020;34(11):1133\u201347.","journal-title":"CNS Drugs"},{"issue":"14","key":"2130_CR8","doi-asserted-by":"publisher","first-page":"18515","DOI":"10.18632\/aging.203299","volume":"13","author":"N Hong","year":"2021","unstructured":"Hong N, Ye Z, Lin Y, Liu W, Xu N, Wang Y. Agomelatine prevents angiotensin II-induced endothelial and mononuclear cell adhesion. Aging. 2021;13(14):18515\u201326.","journal-title":"Aging"},{"issue":"2a","key":"2130_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0002-9149(01)02321-9","volume":"89","author":"T Unger","year":"2002","unstructured":"Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89(2a):3. A-9A; discussion 10A.","journal-title":"Am J Cardiol"},{"key":"2130_CR10","first-page":"1307","volume":"11","author":"R Kang","year":"2015","unstructured":"Kang R, He Y, Yan Y, Li Z, Wu Y, Guo X, et al. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. Neuropsychiatr Dis Treat. 2015;11:1307\u201311.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2130_CR11","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2147\/NDT.S167608","volume":"14","author":"T Che","year":"2018","unstructured":"Che T, Teng X, Huang Q, Mu Y, Tang X, Mu X, et al. Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial. Neuropsychiatr Dis Treat. 2018;14:1527\u201333.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2130_CR12","doi-asserted-by":"publisher","first-page":"111807","DOI":"10.1016\/j.biopha.2021.111807","volume":"141","author":"VB Veronesi","year":"2021","unstructured":"Veronesi VB, Pioli MR, de Souza DN, Teixeira CJ, Murata GM, Santos-Silva JC, et al. Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats. Biomed Pharmacother. 2021;141:111807.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"2130_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437\u201341.","journal-title":"Nat Rev Rheumatol"},{"key":"2130_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/CLEP.S353435","volume":"14","author":"M-T Hsieh","year":"2022","unstructured":"Hsieh M-T, Hsieh C-Y, Tsai T-T, Sung S-F. Validation of Stroke Risk Factors in Patients with Acute Ischemic Stroke, Transient Ischemic Attack, or Intracerebral Hemorrhage on Taiwan\u2019s National Health Insurance Claims Data. Clin Epidemiol. 2022;14:327\u201335.","journal-title":"Clin Epidemiol"},{"issue":"1\u20133","key":"2130_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ejphar.2012.12.009","volume":"701","author":"A Mart\u00ednez-\u00c1guila","year":"2013","unstructured":"Mart\u00ednez-\u00c1guila A, Fonseca B, Bergua A, Pintor J. Melatonin analogue agomelatine reduces rabbit\u2019s intraocular pressure in normotensive and hypertensive conditions. Eur J Pharmacol. 2013;701(1\u20133):213\u20137.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2130_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/opo.12189","volume":"35","author":"N Pescosolido","year":"2015","unstructured":"Pescosolido N, Gatto V, Stefanucci A, Rusciano D. Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients. Ophthalmic Physiol Opt. 2015;35(2):201\u20135.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"8","key":"2130_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/1440-1681.12942","volume":"45","author":"J Baker","year":"2018","unstructured":"Baker J, Kimpinski K. Role of melatonin in blood pressure regulation: An adjunct anti-hypertensive agent. Clin Exp Pharmacol Physiol. 2018;45(8):755\u201366.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"2130_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1600-079X.2007.00436.x","volume":"42","author":"F Simko","year":"2007","unstructured":"Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res. 2007;42(4):319\u201322.","journal-title":"J Pineal Res"},{"issue":"10","key":"2130_CR19","doi-asserted-by":"publisher","first-page":"17920","DOI":"10.3390\/ijms151017920","volume":"15","author":"O Pechanova","year":"2014","unstructured":"Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation. Int J Mol Sci. 2014;15(10):17920\u201337.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2130_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1600-079X.2008.00657.x","volume":"46","author":"EK Tamura","year":"2009","unstructured":"Tamura EK, Cecon E, Monteiro AW, Silva CL, Markus RP. Melatonin inhibits LPS-induced NO production in rat endothelial cells. J Pineal Res. 2009;46(3):268\u201374.","journal-title":"J Pineal Res"},{"key":"2130_CR21","doi-asserted-by":"publisher","first-page":"109646","DOI":"10.1016\/j.intimp.2022.109646","volume":"115","author":"NM Mahmoud","year":"2023","unstructured":"Mahmoud NM, Elshazly SM, Hassan AA, Soliman E. Agomelatine improves streptozotocin-induced diabetic nephropathy through melatonin receptors\/SIRT1 signaling pathway. Int Immunopharmacol. 2023;115:109646.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2130_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/fcp.12413","volume":"33","author":"M Ozcan","year":"2019","unstructured":"Ozcan M, Canpolat S, Bulmus O, Ulker N, Tektemur A, Tekin S, et al. Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin-induced diabetes in mice. Fundam Clin Pharmacol. 2019;33(2):170\u201380.","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"2130_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.7150\/ijbs.66871","volume":"18","author":"S Shen","year":"2022","unstructured":"Shen S, Liao Q, Wong YK, Chen X, Yang C, Xu C, et al. The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer\u2019s disease. Int J Biol Sci. 2022;18(3):983\u201394.","journal-title":"Int J Biol Sci"},{"key":"2130_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1126\/scisignal.aan6622","volume":"11","author":"A Karamitri","year":"2018","unstructured":"Karamitri A, Plouffe B, Bonnefond A, Chen M, Gallion J, Guillaume JL, et al. Type 2 diabetes-associated variants of the MT(2) melatonin receptor affect distinct modes of signaling. Sci Signal. 2018;11:545.","journal-title":"Sci Signal"},{"key":"2130_CR25","doi-asserted-by":"publisher","unstructured":"Owino S, S\u00e1nchez-Breta\u00f1o A, Tchio C, Cecon E, Karamitri A, Dam J et al. Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI3K activity. J Pineal Res. 2018;64(3) :e12462. https:\/\/doi.org\/10.1111\/jpi.12462.","DOI":"10.1111\/jpi.12462"},{"issue":"5","key":"2130_CR26","first-page":"1310","volume":"10","author":"P Jia","year":"2018","unstructured":"Jia P, Liu C, Wu N, Jia D, Sun Y. Agomelatine protects against myocardial ischemia reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am J Transl Res. 2018;10(5):1310\u201323.","journal-title":"Am J Transl Res"},{"key":"2130_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.biochi.2022.01.001","volume":"202","author":"R Patel","year":"2022","unstructured":"Patel R, Parmar N, Pramanik Palit S, Rathwa N, Ramachandran AV, Begum R. Diabetes mellitus and melatonin: Where are we? Biochimie. 2022;202:2\u201314.","journal-title":"Biochimie"},{"issue":"6","key":"2130_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.cmet.2016.04.009","volume":"23","author":"T Tuomi","year":"2016","unstructured":"Tuomi T, Nagorny CLF, Singh P, Bennet H, Yu Q, Alenkvist I, et al. Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. Cell Metab. 2016;23(6):1067\u201377.","journal-title":"Cell Metab"},{"issue":"4","key":"2130_CR29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.clnu.2017.04.003","volume":"37","author":"J Lopez-Minguez","year":"2018","unstructured":"Lopez-Minguez J, Saxena R, Band\u00edn C, Scheer FA, Garaulet M. Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study. Clin Nutr. 2018;37(4):1133\u201340.","journal-title":"Clin Nutr"},{"key":"2130_CR30","doi-asserted-by":"publisher","first-page":"115909","DOI":"10.1016\/j.bcp.2023.115909","volume":"218","author":"D Zhang","year":"2023","unstructured":"Zhang D, Jia X, Lin D, Ma J. Melatonin and ferroptosis: Mechanisms and therapeutic implications. Biochem Pharmacol. 2023;218:115909.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"2130_CR31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.2174\/156652407782564444","volume":"7","author":"A Catal\u00e1","year":"2007","unstructured":"Catal\u00e1 A. The ability of melatonin to counteract lipid peroxidation in biological membranes. Curr Mol Med. 2007;7(7):638\u201349.","journal-title":"Curr Mol Med"},{"issue":"2","key":"2130_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/13813455.2020.1838550","volume":"129","author":"D Sezgin","year":"2023","unstructured":"Sezgin D, Aslan G, Sahin K, Tuzcu M, \u0130lhan N, Sahna E. The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats. Arch Physiol Biochem. 2023;129(2):476\u201383.","journal-title":"Arch Physiol Biochem"},{"issue":"7","key":"2130_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40263-018-0537-1","volume":"32","author":"S Billioti de Gage","year":"2018","unstructured":"Billioti de Gage S, Collin C, Le-Tri T, Pariente A, B\u00e9gaud B, Verdoux H, et al. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. CNS Drugs. 2018;32(7):673\u201384.","journal-title":"CNS Drugs"},{"issue":"9","key":"2130_CR34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40263-016-0351-6","volume":"30","author":"G Perlemuter","year":"2016","unstructured":"Perlemuter G, Cacoub P, Valla D, Guyader D, Saba B, Batailler C, et al. Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients. CNS Drugs. 2016;30(9):877\u201388.","journal-title":"CNS Drugs"},{"issue":"4","key":"2130_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40263-019-00611-9","volume":"33","author":"M Pladevall-Vila","year":"2019","unstructured":"Pladevall-Vila M, Potteg\u00e5rd A, Schink T, Reutfors J, Morros R, Poblador-Plou B, et al. Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources. CNS Drugs. 2019;33(4):383\u201395.","journal-title":"CNS Drugs"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02130-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02130-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02130-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:11:11Z","timestamp":1774883471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02130-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2130"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02130-2","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Tri-Services General Hospital (C202405054) in Taiwan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Li-Ting Kao reports research funding outside the submitted work from IQVIA. No other disclosures were reported.Thelare no competing interests. authors dec","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}